1. Pure therapies: omega-3 fatty acids, L-methylfolate, or mild remedy
2. Antipsychotics: aripiprazole, risperidone, or quetiapine
3. Antidepressants: bupropion, imipramine, or mirtazapine
5. Liothyronine (T3)
When speedy reduction is the precedence, an antipsychotic may be the only option. For favorable tolerability, there may be bupropion or a pure remedy, and lithium has sturdy antisuicide results, if that could be a concern. However what if insomnia is the chief criticism? Mirtazapine is tempting right here, however this treatment carries a threat of weight achieve and didn’t carry out effectively in a number of current, well-designed augmentation trials.2 As an alternative, a normal hypnotic could also be choice when sufferers proceed to have melancholy and insomnia on an antidepressant, however not simply any hypnotic.
Eszopiclone: The Science Behind Its Potential Impact on Melancholy
Within the early 2000s, a gaggle of sleep researchers got down to examine whether or not hypnotics might enhance temper in sufferers with melancholy and insomnia. The outcomes didn’t pan out precisely as anticipated, however they level the way in which towards a drugs with distinctive potential in melancholy.
However first, investigators needed to overcome a hurdle. On the time, it was thought that hypnotics may trigger melancholy by their sedative results. That concern was partly put to relaxation in a 1999 examine that examined whether or not zolpidem might relieve selective serotonin reuptake inhibitor [SSRI]-induced insomnia in sufferers who had in any other case recovered on the antidepressant. The sleep issues improved with zolpidem and, to the investigators’ reduction, the sedating treatment didn’t worsen melancholy.3
Buoyed by this consequence, the producer of eszopiclone funded a big trial to see if melancholy may truly enhance with their hypnotic. 5 hundred and forty-five sufferers with melancholy and insomnia have been randomized to obtain both eszopiclone 3mg or placebo whereas concurrently beginning a trial of fluoxetine. As anticipated, the hypnotic improved sleep, however it additionally improved temper signs that have been unrelated to sleep. In comparison with placebo, those that obtained eszopiclone skilled a extra speedy and full restoration from melancholy.4
The identical group repeated the examine with zolpidem ER in a big trial of comparable design. As soon as once more, the hypnotic improved sleep, however this time there was no change in temper.4 Replication in China introduced the identical adverse outcomes, and final yr zolpidem failed once more to elevate temper or scale back suicidality when added to an SSRI in a randomized trial of sufferers with melancholy, insomnia, and suicidality.4,5
In the meantime, eszopiclone repeated its success, bettering temper and insomnia in 2 extra trials, 1 of which concerned peri- and postmenopausal girls with insomnia and depressive signs.6,7 Generalized anxiousness dysfunction additionally improved when eszopiclone was added to an SSRI in a big manufacturer-supported trial that replicated the design of eszopiclone’s pivotal melancholy trial.8
Each the zolpidem and eszopiclone research concerned most of the similar investigators, who had pursued this work with the concept any hypnotic that improved sleep would not directly enhance temper. However to at the present time eszopiclone stays the one hypnotic with distinct antidepressant results (ramelteon has gentle preventative advantages in bipolar dysfunction however isn’t recognized to deal with melancholy).9 Whether or not it is a statistical fluke or a real distinction is tough to say, as eszopiclone has not gone head-to-head in opposition to different hypnotics in melancholy. Nevertheless, eszopiclone does have a singular mechanism of motion that may clarify its antidepressant results. To know that we have to flip to the GABAA receptor.
In comparison with the benzodiazepines, the z-hypnotics have extra restricted results on GABAA, which is assumed to elucidate why they deal with sleep however not anxiousness. Particularly, the z-hypnotics are selective for the sleep-inducing GABAA α-1 subunit, whereas benzodiazepines have extra results on the α-2 and -3 subunits which might be concerned in anxiousness and melancholy. However eszopiclone is an exception. It acts at the entire α subunits, and may very well be slightly extra selective for the anxiolytic α-2 and-3.10 This impact is furthered by eszopiclone’s lively metabolite, desmethylzopiclone, which is a selective partial agonist at α-2 and -3 with little or no α-1 exercise (that could be a good factor, as it will in any other case trigger a whole lot of daytime sedation).11 In animal fashions, desmethylzopiclone diminished anxiousness with out inflicting sedation or motor impairment.12 Its results in people usually are not effectively described, however the trials above give us a touch, and the corporate that launched eszopiclone has patented this metabolite as a possible anxiolytic.
On this means, eszopiclone resembles the benzodiazepines, which have been used to deal with melancholy and hasten the response to antidepressants in over 3 dozen managed trials.13 In most of these trials, their antidepressant results have been unbiased of their anxiolytic results, simply as eszopiclone handled signs of melancholy that have been unrelated to sleep.
Regardless of this analysis, benzodiazepines usually are not used routinely for melancholy due to their threat of tolerance and abuse. These dangers may additionally apply to eszopiclone, however the trials above present some reassurance. In a number of of them, eszopiclone was changed with a placebo after 2 months of remedy with none lack of the antidepressant and anxiolytic beneficial properties. Nor was there any rebound insomnia and, in some research, it stabilized sleep patterns in a means that continued after the hypnotic was stopped.4,8
Does all this elevate eszopiclone to the extent of antidepressant augmentation? Probably. It does have extra optimistic outcomes than some the augmentation methods which might be endorsed by evidence-based pointers.1 However there are 2 caveats. First, eszopiclone was solely studied in sufferers with comorbid insomnia, however this isn’t a significant hurdle as it’s the uncommon affected person with melancholy who doesn’t battle with sleep (about 15%).14 Extra considerably, eszopiclone was began in tandem with an antidepressant in these augmentation trials, so we have no idea if it might flip issues round when added later, after a number of antidepressant failures.
The Backside Line
When deciding on a hypnotic in melancholy or generalized anxiousness dysfunction, eszopiclone ought to be on the record. The remedy needn’t be long-term. Most sufferers have been in a position to taper off the hypnotic after restoration. To bolster these odds, begin out with the expectation of short-term use and information the affected person towards behavioral interventions for long-term upkeep of sleep.
Dr Aiken is the Temper Issues Part Editor for Psychiatric InstancesTM, the Editor in Chief of The Carlat Psychiatry Report, and the director of the Mood Treatment Center. He has written a number of books on temper issues, most lately The Depression and Bipolar Workbook. He might be heard within the weekly Carlat Psychiatry Podcast together with his cohost Kellie Newsome, PMH-NP. The creator doesn’t settle for honoraria from pharmaceutical corporations however receives royalties from PESI for The Depression and Bipolar Workbook and from W.W. Norton & Co. for Bipolar, Not So Much.
1. Giakoumatos CI, Osser D. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on unipolar nonpsychotic depression. Harv Rev Psychiatry. 2019;27(1):33-52.
2. Jordan T, Aiken C. Mirtazapine augmentation: Running low on rocket fuel. The Carlat Psychiatry Report. September 2019. Accessed August 27, 2021.
3. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry. 1999;60(10):668-676.
4. Kishi T, Matsunaga S, Iwata N. Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci. 2017;267(2):149-161.
5. McCall WV, Benca RM, Rosenquist PB, et al. Reducing suicidal ideation through insomnia treatment (rest-it): a randomized clinical trial. Am J Psychiatry. 2019;176(11):957-965.
6. McCall WV, Blocker JN, D’Agostino R Jr, et al. Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. J Clin Sleep Med. 2010;6(4):322-329.
7. Joffe H, Petrillo L, Viguera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol. 2010;202(2):171.e1-171.e11.
8. Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008;65(5):551-562.
9. Kishi T, Nomura I, Sakuma Okay, et al. Melatonin receptor agonists-ramelteon and melatonin-for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. Neuropsychiatr Dis Deal with. 2019;15:1479-1486.
10. Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010;24(11):1601-1612.
11. Fleck MW. Molecular actions of (S)-desmethylzopiclone (SEP-174559), an anxiolytic metabolite of zopiclone. J Pharmacol Exp Ther. 2002;302(2):612-618.
12. Carlson JN, Haskew R, Wacker J, et al. Sedative and anxiolytic effects of zopiclone’s enantiomers and metabolite. Eur J Pharmacol. 2001;415(2-3):181-189.
13. Benasi G, Guidi J, Offidani E, et al. Benzodiazepines as a monotherapy in depressive disorders: a systematic review. Psychother Psychosom. 2018;87(2):65-74
14. Sunderajan P, Gaynes BN, Wisniewski SR, et al. Insomnia in patients with depression: a STAR*D report. CNS Spectr. 2010;15(6):394-404.